Series B round brings $21mm to Kleo
Executive Summary
Kleo Pharmaceuticals Inc. (immuno-oncology) raised $21mm through an oversubscribed Series B round led by PeptiDream (development partner under a 2017 deal) and including Biohaven Pharmaceuticals. The company is developing cancer therapies based on its Antibody Recruiting Molecules (ARM) technology, and will use the Series B funds to advance its first candidates into human studies.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice